Encephalopathy News and Research

RSS

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

Regular physical trauma may put professional football players at increased risk for hypertension

The regular physical trauma that appears to put professional football players at risk for degenerative brain disease may also increase their risk for hypertension and cardiovascular disease, researchers say.

9 Sep 2015

Allergan announces positive results from AVYCAZ Phase III studies for treatment of cUTI

Allergan plc. today announced positive topline results from RECAPTURE 1 and 2, the pivotal Phase III studies evaluating the antibiotic AVYCAZ (ceftazidime-avibactam) as a treatment for adult hospitalized patients with complicated urinary tract infections (cUTI), including pyelonephritis.

2 Sep 2015

Newly discovered prion causes Multiple System Atrophy

Multiple System Atrophy (MSA), a neurodegenerative disorder with similarities to Parkinson's disease, is caused by a newly discovered type of prion, akin to the misfolded proteins involved in incurable progressive brain diseases such Creutzfeldt-Jakob Disease (CJD), according to two new research papers led by scientists at UC San Francisco.

1 Sep 2015

FAU neuroscientist develops Quick Dementia Rating System comparable to gold standard clinical tests

Determining whether or not an individual has dementia and to what degree is a long and laborious process that can take an experienced professional such as a clinician about four to five hours to administer, interpret and score the test results. A leading neuroscientist at Florida Atlantic University has developed a way for a layperson to do this in three to five minutes with results that are comparable to the "gold standard" dementia tests used by clinicians today.

13 Aug 2015

Early exposure to repetitive head impacts linked to later life structural brain changes among former NFL players

Former National Football League (NFL) players who started playing tackle football before the age of 12 were found to have a higher risk of altered brain development compared to those who started playing at a later age. The study is the first to demonstrate a link between early exposure to repetitive head impacts and later life structural brain changes.

11 Aug 2015

New study reveals how infectious proteins spread from gut to the brain

Diagnosis of deadly brain conditions could be helped by new research that shows how infectious proteins that cause the disease spread.

5 Aug 2015

Extremes of stroke symptoms attract misdiagnoses

Patients with very mild or very severe stroke symptoms are at the greatest risk of being misdiagnosed in the emergency department, research suggests.

24 Jul 2015

Two UM researchers receive $500,000 to improve treatment for mild traumatic brain injury

Two University of Montana researchers were among six final winners nationally to receive $500,000 from the Head Health Challenge I, an up-to-$10 million program sponsored by General Electric Co. and the National Football League.

24 Jul 2015

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy.

23 Jul 2015

New research offers potential for early intervention to prevent neurodegenerative diseases

New research led by investigators at Beth Israel Deaconess Medical Center provides the first direct evidence linking traumatic brain injury to Alzheimer's disease and chronic traumatic encephalopathy (CTE) -- and offers the potential for early intervention to prevent the development of these debilitating neurodegenerative diseases.

16 Jul 2015

Envarsus XR receives FDA approval for treatment of kidney transplant recipients

Veloxis Pharmaceuticals A/S today announced U.S. Food and Drug Administration approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR.

11 Jul 2015

Research shows how prion-like proteins critical for maintaining long-term memories

Research from Eric Kandel's lab at Columbia University Medical Center has uncovered further evidence of a system in the brain that persistently maintains memories for long periods of time. And paradoxically, it works in the same way as mechanisms that cause mad cow disease, kuru, and other degenerative brain diseases.

3 Jul 2015

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant.

19 Jun 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015.

28 May 2015

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration for Xifaxan 550 mg for the treatment of IBS-D in adults.

28 May 2015

New article shows link between head injuries and neurodegenerative disease in rugby union players

A new article publishing online today in the Quarterly Journal of Medicine has reported the first case showing an association between exposure to head injuries in rugby union players and an increased risk in neurodegenerative disease.

24 May 2015

Available research does not support link between chronic traumatic encephalopathy and sports

Available research does not support the contention that athletes are uniquely at risk of chronic traumatic encephalopathy (CTE) or other neurodegenerative disorders, according to a review in the June issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

21 May 2015

CLDF collaborates with Walgreens to offer free rapid HCV testing

The Chronic Liver Disease Foundation announced today that it's collaborating with Walgreens to offer free hepatitis C (HCV) testing with the OraQuick HCV Rapid Test at more than 60 Walgreens retail pharmacies in 12 major cities throughout the country.

19 May 2015